KalVista Pharmaceuticals to Recognize HAE Day 2017
May 15 2017 - 7:30AM
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today
joins the Hereditary Angioedema Association (HAEA) and the entire
patient community in recognizing May 16 as HAE Day.
“KalVista is proud to support HAEA in raising
awareness of the importance of continued research and development
of treatments for HAE,” said Andrew Crockett, Chief Executive
Officer of KalVista. “There are still many HAE patients who are
misdiagnosed and whose symptoms are not well-managed. To better
support them and offer improved therapeutic alternatives, we are
committed to the development of a best-in-class oral therapy for
HAE.”
Going forward, KalVista will be working with
HAEA to support their mission to serve persons with angioedema.
HAEA’s 2017 HAE Day initiative is “Stand Up Strong,” a unifying
call to action for the HAE community and a celebration of work
being done by those who make a difference every day by raising HAE
awareness within their communities.
KalVista will be participating in a NASDAQ
closing bell ceremony, today, May 15, 2017 and will honor the
patients and supporters with recognition of HAE Day during this
ceremony.
About Hereditary Angioedema
(HAE)Hereditary angioedema (HAE) is a rare and potentially
life-threatening genetic condition that occurs in approximately 1
in 50,000 people. HAE patients are susceptible to sudden and
prolonged attacks of edema, which often occur in the hands, feet,
face, gastrointestinal tract, and airway. Attacks can result in
severe swelling and pain, airway blockage, and nausea.
About hae day :-)On May 16th,
hae day :-) was established by Congressional Resolution to raise
awareness of HAE among the general public and medical community in
order to support better care, increase earlier and more accurate
diagnosis, and spread the knowledge that HAE patients can achieve
lifelong health.
About the US HAEAThe US HAEA is
a non-profit patient advocacy organization serving Hereditary
Angioedema patients. The Organization was founded and staffed
by HAE patients and caregivers and provides patients and families
with a support network and a wide range of services to help them
lead a healthy life.
About KalVista Pharmaceuticals,
Inc.KalVista Pharmaceuticals, Inc. is a pharmaceuticals
company focused on the discovery, development, and
commercialization of small molecule protease inhibitors for
diseases with significant unmet need. The initial focus is on
inhibitors of plasma kallikrein, which is an important component of
the body’s inflammatory response, and which in excess can lead to
increased vascular permeability, edema and inflammation. KalVista
has developed a proprietary portfolio of novel, small molecule
plasma kallikrein inhibitors initially targeting hereditary
angioedema (HAE) and diabetic macular edema (DME). The Company has
created a structurally diverse portfolio of oral plasma kallikrein
inhibitors from which it plans to select multiple drug candidates
to advance into clinical trials for HAE. The first of this planned
portfolio of programs, KVD818, is currently in a first-in-human
study that commenced in the second half of 2016, and additional
program candidates are in preclinical development. KalVista’s most
advanced program, an intravitreally administered plasma kallikrein
inhibitor known as KVD001, has successfully completed its
first‑in‑human study in patients with DME and is being prepared for
Phase 2 studies in 2017.
For more information, please visit
www.KalVista.com.
Forward-Looking StatementsThis
press release contains "forward-looking" statements within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, available funding
and future clinical trial timing and results. Further information
on potential risk factors that could affect our business and its
financial results are detailed in the definitive proxy statement
filed on October 28, 2016, our most recent Quarterly Report on Form
10-Q, and other reports as filed from time to time with
the Securities and Exchange Commission. We undertake no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
Contact:
KalVista Pharmaceuticals, Inc.
Leah Monteiro, Corporate Communications & Investor Relations
857-999-0808
lmm@KalVista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Aug 2024 to Sep 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Sep 2023 to Sep 2024